OCGN Stock Chart & Stats
$21.47
-$0.93(-4.15%)
At close: 4:00 PM EDT
$21.47
-$0.93(-4.15%)
Day’s Range― - ―
52-Week Range$14.44 - $45.50
Previous CloseN/A
Volume141.00
Average Volume (3M)229.00
Market Cap
$7.21B
Enterprise Value$594.30
Total Cash (Recent Filing)$31.86M
Total Debt (Recent Filing)$33.30M
Price to Earnings (P/E)―
Beta-0.53
Next Earnings
Nov 10, 2026EPS Estimate
-0.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding338,521,850
10 Day Avg. Volume181
30 Day Avg. Volume229
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)-33.31
Price to Sales (P/S)91.83
P/FCF Ratio-7.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$189.62Price Target Upside783.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Progress (OCU410)FDA clearance to initiate a registrational Phase III and RMAT status materially strengthens the regulatory pathway. This durable milestone reduces program risk, supports prioritized FDA interactions, and underpins the company's plan to pursue BLA filings by 2028, improving long-term approval odds.
Phase II Efficacy And Safety SignalsStatistically significant efficacy with a favorable safety record in Phase II provides durable evidence of biological activity and tolerability. Such clinical validation increases the probability of success in pivotal trials and strengthens future discussions with payers and partners about product value.
Extended Cash Runway From FinancingA sizeable convertible note raise and stated cash through mid‑2026 materially extends runway into 2028. This durable capital buffer allows execution of three late‑stage programs, reduces immediate refinancing urgency, and supports meeting near‑term regulatory and clinical milestones.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow means the business cannot internally fund development. Over time this forces repeated external financings, raising dilution and strategic risk, and can divert management attention from commercialization to capital sourcing during critical trial and filing periods.
Stressed Balance Sheet And LeverageA rapidly higher debt load combined with negative equity reduces financial flexibility and increases vulnerability to adverse outcomes. Elevated leverage limits options for strategic investments or partnerships, raises refinancing risk, and can constrain commercial launch support if approvals occur.
Ongoing Reliance On Contingent FinancingExplicit dependency on contingent levers (PRV, warrant exercises, BD/licensing, shareholder vote to increase shares) signals structural funding reliance. Such conditional financing paths carry dilution and execution risk, and outcomes are uncertain, affecting long‑term capitalization for commercialization.
Ocugen News
OCGN FAQ
What was Ocugen Inc’s price range in the past 12 months?
Ocugen Inc lowest stock price was $14.44 and its highest was $45.50 in the past 12 months.
What is Ocugen Inc’s market cap?
Ocugen Inc’s market cap is $7.21B.
When is Ocugen Inc’s upcoming earnings report date?
Ocugen Inc’s upcoming earnings report date is Nov 10, 2026 which is in 95 days.
How were Ocugen Inc’s earnings last quarter?
Ocugen Inc released its earnings results on Aug 06, 2026. The company reported -$1.204 earnings per share for the quarter, missing the consensus estimate of -$0.912 by -$0.292.
Is Ocugen Inc overvalued?
According to Wall Street analysts Ocugen Inc’s price is currently Undervalued.
Does Ocugen Inc pay dividends?
Ocugen Inc does not currently pay dividends.
What is Ocugen Inc’s EPS estimate?
Ocugen Inc’s EPS estimate is -0.89.
How many shares outstanding does Ocugen Inc have?
Ocugen Inc has 338,521,850 shares outstanding.
What happened to Ocugen Inc’s price movement after its last earnings report?
Ocugen Inc reported an EPS of -$1.204 in its last earnings report, missing expectations of -$0.912. Following the earnings report the stock price went down -4.444%.
Which hedge fund is a major shareholder of Ocugen Inc?
Currently, no hedge funds are holding shares in MX:OCGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ocugen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$189.62 (783.17% Upside)
$189.62 (783.17% Upside)
Blogger Sentiment
Bullish
MX:OCGN Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $445.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
15.59%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-11.72%
Trailing 12-Months
Company Description
Ocugen Inc
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
OCGN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed multiple significant clinical and regulatory advances — FDA clearance to start the Phase 3 GA trial with RMAT designation, strong Phase II efficacy signals for OCU410, completed enrollments and clear timelines for Phase III readouts for OCU400 and OCU410ST, manufacturing PPQs complete, a $130M financing and cash runway into 2028, and a MENA partnership — all material execution milestones. Offsetting these positives are rising operating expenses and a larger reported net loss per share, continued dependence on additional financing levers (which could be dilutive), and customary regulatory/timing and commercialization uncertainties. Overall, the operational and clinical progress and strengthened balance sheet outweigh the financial and execution risks discussed on the call.View all MX:OCGN earnings summariesOCGN Stock 12 Month Forecast
Average Price Target
$189.62
▲(783.17% Upside)